| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| I J Andersson, A Barlind, H C Nyström, B Olsson, O Skøtt, R Mobini, M Johansson, G Bergströ. Reduced sympathetic responsiveness as well as plasma and tissue noradrenaline concentration in growth hormone transgenic mice. Acta physiologica Scandinavica. vol 182. issue 4. 2005-02-16. PMID:15569098. |
acromegaly [overproduction of growth hormone (gh)] and gh deficiency have both been associated with alterations in autonomic nervous system function. |
2005-02-16 |
2023-08-12 |
mouse |
| J J Kopchic. Discovery and development of a new class of drugs: GH antagonists. Journal of endocrinological investigation. vol 26. issue 10 Suppl. 2005-02-15. PMID:15497656. |
acromegaly), or when gh action has been implicated in disease states (e.g., cancer- or diabetes-induced end-organ damage). |
2005-02-15 |
2023-08-12 |
mouse |
| S Grottoli, V Gasco, F Ragazzoni, E Ghig. Hormonal diagnosis of GH hypersecretory states. Journal of endocrinological investigation. vol 26. issue 10 Suppl. 2005-02-15. PMID:15497657. |
apart from these "functional" hypersecretory state, the classic organic gh hypersecretory state is represented by acromegaly or giantism. |
2005-02-15 |
2023-08-12 |
Not clear |
| S Grottoli, V Gasco, F Ragazzoni, E Ghig. Hormonal diagnosis of GH hypersecretory states. Journal of endocrinological investigation. vol 26. issue 10 Suppl. 2005-02-15. PMID:15497657. |
in the appropriate clinical context of acromegalic features, evidence of concomitant marked gh and igf-i hypersecretion at baseline demonstrates active acromegaly or giantism and indicates the need for magnetic resonance imaging in order to verify the presence of a pituitary tumor. |
2005-02-15 |
2023-08-12 |
Not clear |
| S Grottoli, V Gasco, F Ragazzoni, E Ghig. Hormonal diagnosis of GH hypersecretory states. Journal of endocrinological investigation. vol 26. issue 10 Suppl. 2005-02-15. PMID:15497657. |
however, as random measurement of basal gh levels is not reliable for definite diagnosis of acromegaly, it is considered mandatory to rely on the lack of gh suppression below 1 microg/l during oral glucose tolerance test (ogtt) coupled with elevated igf-i levels. |
2005-02-15 |
2023-08-12 |
Not clear |
| S Grottoli, V Gasco, F Ragazzoni, E Ghig. Hormonal diagnosis of GH hypersecretory states. Journal of endocrinological investigation. vol 26. issue 10 Suppl. 2005-02-15. PMID:15497657. |
it has been clearly demonstrated that an extended exposure to gh and igf-i excess level, even if slight, has a very harmful effect on patients; therefore early diagnosis of acromegaly and appropriate definition of its cure are of fundamental extreme in order to plan a prompt and appropriate therapeutic intervention(s) guaranteed also by the continuous improvement in the therapeutic tools available to treat this systemic disease. |
2005-02-15 |
2023-08-12 |
Not clear |
| M Arosio, S Cannavò, P Epaminonda, C Ronchi, I Chiodini, G Add. Therapy for the syndromes of GH excess. Journal of endocrinological investigation. vol 26. issue 10 Suppl. 2005-02-15. PMID:15497658. |
this short review summarizes the results of treatments now available in italy for the management of gh and igf-i excess due to primary pituitary somatotroph adenoma, which accounts for over 99% of cases of acromegaly. |
2005-02-15 |
2023-08-12 |
Not clear |
| M Arosio, S Cannavò, P Epaminonda, C Ronchi, I Chiodini, G Add. Therapy for the syndromes of GH excess. Journal of endocrinological investigation. vol 26. issue 10 Suppl. 2005-02-15. PMID:15497658. |
goals of treatment of acromegaly should now include, in addition to the reduction of tumor bulk and symptomatic relief, the lowering of gh circulating concentrations to below a critical level (2.5 microg/l, "safe" gh), the normalization of serum igf-i concentrations according to age, improvement (or at least not worsening) of co-morbidities (diabetes mellitus, hypertension, cardiomyopathy, sleep-apnea), the decrease of the risk of premature mortality. |
2005-02-15 |
2023-08-12 |
Not clear |
| P J Traine. Lessons from 6 years of GH receptor antagonist therapy for acromegaly. Journal of endocrinological investigation. vol 26. issue 10 Suppl. 2005-02-15. PMID:15497659. |
lessons from 6 years of gh receptor antagonist therapy for acromegaly. |
2005-02-15 |
2023-08-12 |
Not clear |
| P J Traine. Lessons from 6 years of GH receptor antagonist therapy for acromegaly. Journal of endocrinological investigation. vol 26. issue 10 Suppl. 2005-02-15. PMID:15497659. |
pegvisomant is a gh receptor antagonist and a new agent for the medical management of acromegaly. |
2005-02-15 |
2023-08-12 |
Not clear |
| A Colao, R Pivonello, P Cappabianca, R S Auriemma, M C De Martino, A Ciccarelli, E de Divitiis, G Lombard. The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs. Journal of endocrinological investigation. vol 26. issue 10 Suppl. 2005-02-15. PMID:15497660. |
the use of a gh receptor antagonist in patients with acromegaly resistant to somatostatin analogs. |
2005-02-15 |
2023-08-12 |
Not clear |
| A Colao, R Pivonello, P Cappabianca, R S Auriemma, M C De Martino, A Ciccarelli, E de Divitiis, G Lombard. The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs. Journal of endocrinological investigation. vol 26. issue 10 Suppl. 2005-02-15. PMID:15497660. |
pegvisomant, a gh receptor antagonist, is a new pharmaceutical approach to acromegaly. |
2005-02-15 |
2023-08-12 |
Not clear |
| Christos Zavos, Charalampos Andreadis, Nikolaos Diamantopoulos, Despina Mouratido. A hypothesis on the role of insulin-like growth factor I in testicular germ cell tumours. Medical hypotheses. vol 63. issue 3. 2005-02-10. PMID:15288379. |
scattered publications report development of gct secondary to acromegaly or long-term gh replacement therapy. |
2005-02-10 |
2023-08-12 |
Not clear |
| Massimo Terzolo, Giuseppe Reimondo, Maurizio Gasperi, Renato Cozzi, Rosario Pivonello, Giovanni Vitale, Alfredo Scillitani, Roberto Attanasio, Elisabetta Cecconi, Fulvia Daffara, Ezio Gaia, Ennio Martino, Gaetano Lombardi, Alberto Angeli, Annamaria Cola. Colonoscopic screening and follow-up in patients with acromegaly: a multicenter study in Italy. The Journal of clinical endocrinology and metabolism. vol 90. issue 1. 2005-02-10. PMID:15507515. |
acromegaly is an infrequent disease attributable to endogenous excess of gh and igf-i. |
2005-02-10 |
2023-08-12 |
human |
| O Ionescu, E Sonnet, N Roudaut, F Prédine-Hug, V Kerla. [Oral manifestations of endocrine dysfunction]. Annales d'endocrinologie. vol 65. issue 5. 2005-01-18. PMID:15550888. |
objective manifestations, such as ophtalmos in hyperthyroidism, signs of hypersecretion of gh in acromegaly, are easily recognized. |
2005-01-18 |
2023-08-12 |
Not clear |
| O Tiryakioğlu, P Kadiolgu, N U Canerolgu, H Hatem. Age dependency of serum insulin - like growth factor (IGF)-1 in healthy Turkish adolescents and adults. Indian journal of medical sciences. vol 57. issue 12. 2005-01-05. PMID:14701946. |
measurements of igf-1 are useful for diagnosis and follow-up of patients with acromegaly and the diagnosis of gh deficiency in children. |
2005-01-05 |
2023-08-12 |
human |
| James Gibney, Gudmundur Johannsso. Safety of growth hormone replacement therapy in adults. Expert opinion on drug safety. vol 3. issue 4. 2005-01-04. PMID:15268648. |
available experience from long-term replacement therapy, studies using supraphysiological doses of gh in adults and lessons learned from patients with acromegaly who have high endogenous gh levels over many years, is considered. |
2005-01-04 |
2023-08-12 |
human |
| Giovanni V Frajese, Norman F Taylor, Paul J Jenkins, G Michael Besser, John P Monso. Modulation of cortisol metabolism during treatment of acromegaly is independent of body composition and insulin sensitivity. Hormone research. vol 61. issue 5. 2004-12-22. PMID:15004437. |
the set point of cortisol-cortisone conversion is shifted in the direction of cortisone by the inhibition of the activity of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-hsd1) during adult gh replacement and in active acromegaly. |
2004-12-22 |
2023-08-12 |
Not clear |
| A Lania, G Mantovani, E Ferrante, L M Zavanone, M Locatelli, S Corbetta, P Beck-Peccoz, A Spad. Gonadotropin-releasing hormone initiates multiple signaling pathways in human GH-secreting adenomas. Journal of endocrinological investigation. vol 27. issue 4. 2004-12-09. PMID:15233551. |
abnormal gh responses to gnrh test, observed in about 15% of patients with acromegaly, have been reported exclusively in patients bearing tumors without gsp mutation. |
2004-12-09 |
2023-08-12 |
human |
| Nienke R Biermasz, Sjoerd W van Thiel, Alberto M Pereira, Hendrieke C Hoftijzer, Albert M van Hemert, Jan W A Smit, Johannes A Romijn, Ferdinand Roelfsem. Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. The Journal of clinical endocrinology and metabolism. vol 89. issue 11. 2004-12-02. PMID:15531483. |
the long-term impact of acromegaly on subjective well-being after treatment of gh excess is unclear. |
2004-12-02 |
2023-08-12 |
Not clear |